Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 9/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286312 | 0.85 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL9302636 | 0.85 | CA12 (0.62) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL718950 | 0.83 | APP (0.38) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL718613 | 0.79 | CA12 (0.52) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL717450 | 0.79 | CA12 (0.59) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL25490046 | 0.77 | GRM5 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL848355 | 0.77 | CA12 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL29978832 | 0.77 | GRM5 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL935880 | 0.77 | CA12 (0.50) | CA12CA2CA9CA1GRM5 | |
| SCHEMBL9304700 | 0.77 | CA12 (0.62) | CA12CA2CA9CA1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638455-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024138048-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-104302626-A | 4, 4-disubstituted-1, 4-dihydropyrimidines and their use as medicaments for the treatment of hepatitis b | JANSSEN R & D IRELAND | 2015-01-21 | — | — | CN | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |